Gastrointestinal symptoms are by far the most common GLP-1 side effect: nausea, vomiting, diarrhea, and constipation, usually clustered around dose increases. Most of it is manageable and fades with time. The skill is knowing when a symptom has gone past typical and needs a call.
Why GI symptoms are so common
A 2025 systematic review of GLP-1 trials in adults without diabetes found gastrointestinal side effects in roughly 47–84% of people on GLP-1 medications, compared with 13–63% on placebo, mostly nausea, vomiting, diarrhea, and constipation (Moiz et al., Annals of Internal Medicine, 2025, DOI (external link)). Stopping treatment because of side effects was relatively uncommon (0–26% across trials), and serious adverse events were rare (0–10%). So GI symptoms are common, but they're usually manageable and not usually dangerous.
The exact mechanism isn't settled. Slower stomach emptying may contribute, and nausea in particular may come mainly from the drugs' effects on the brain (Wharton et al., Diabetes, Obesity and Metabolism, 2021, DOI (external link)).
How common each one is
Pooled data from the STEP 1–3 trials, with 2,117 people on semaglutide 2.4 mg and 1,262 on placebo, put numbers on each symptom (Wharton et al., 2021):
| Symptom | On semaglutide | On placebo |
|---|---|---|
| Nausea | 43.9% | 16.1% |
| Diarrhea | 29.7% | 15.9% |
| Vomiting | 24.5% | 6.3% |
| Constipation | 24.2% | 11.1% |
Two things stand out. Every one of these also happens on placebo at a meaningful rate, so not every symptom you get is the drug. And most are mild: 99.5% of GI events were non-serious and 98.1% mild-to-moderate, and only 4.3% of people stopped treatment permanently because of them.
A meta-analysis of 19 randomized trials covering 32,884 patients found the same pattern in relative terms: nausea about 2.7 times as common as on placebo, vomiting 3.9 times, diarrhea 2.0 times, and constipation 2.4 times (Tanashat et al., American Journal of Cardiovascular Drugs, 2025, DOI (external link)).
What's typical
Nausea is the most common symptom. It's most frequent during titration, the step-by-step dose increases at the start of treatment. Diarrhea and constipation can both occur, and some people get both at different times. Vomiting is less common than nausea but not rare. GI side effects are dose-dependent, which is why doses are raised gradually (Wharton et al., 2021).
What tends to improve with time
In the STEP trials, GI events were most frequent during or shortly after dose escalation, not steady throughout treatment. Individual episodes were short: the median bout of nausea lasted 8 days, diarrhea 3 days, and vomiting 2 days. Constipation was the exception, with a median episode of 47 days (Wharton et al., 2021). A separate meta-analysis of tirzepatide trials, using trial-sequential analysis, likewise found GI side effects decreased gradually over time and concluded that steady long-term dosing may reduce them (Tong et al., Medicine, 2023, DOI (external link)).
If a fast escalation seems to be causing more symptoms than you can manage, see our guide on slowing down titration.
When to call instead of waiting
Contact your prescriber for persistent vomiting, being unable to keep fluids down, severe abdominal pain, or symptoms that are getting worse over several weeks. Two less common patterns belong on the list too: sudden, severe pain in the upper right abdomen, especially after eating, which can signal gallbladder disease; and, if you also take insulin or a sulfonylurea, shakiness, sweating, or confusion that could be low blood sugar.
Our guide on talking to your doctor about side effects that aren't improving covers how to raise it, and managing GLP-1 side effects has the full red-flag list. For the two most common problems, see our guides on managing nausea and constipation.
Study findings above are attributed to their authors and were located via PubMed.
This article is for general education and is not medical advice. Talk with your prescriber or care team about your own situation.